New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies
Venture capital firm Advent France Biotechnology led fundraising, alongside Crédit Mutuel Innovation and Pierre FabreCo-founded by AFB and leading cancer institutes Gustave Roussy and Institut